FindTrial
Sign In

JAB-21822

DRUG9 trials

Sponsors

Jacobio Pharmaceuticals Co. Ltd., Allist Pharmaceuticals, Inc., Jian Li

Conditions

Advanced Colorectal CancerAdvanced Non-squamous Non-small-cell Lung CancerAppendiceal CancerColorectal CancerFood Effect in Healthy ParticipantsHealthy SubjectsKRAS P.G12CMetastatic Non-squamous Non Small Cell Lung Cancer

Phase 1

A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
Active, not recruitingNCT05009329
Allist Pharmaceuticals, Inc.NSCLC, Solid Tumor
Start: 2021-07-26End: 2026-12-01Updated: 2026-08-13
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
Active, not recruitingNCT05194995
Allist Pharmaceuticals, Inc.Advanced Colorectal Cancer, Appendiceal Cancer, Small Intestinal Cancer
Start: 2022-02-17End: 2026-12-01Updated: 2026-03-16
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
RecruitingNCT05288205
Allist Pharmaceuticals, Inc.Colorectal Cancer, KRAS P.G12C, Non-small Cell Lung Cancer +1
Start: 2022-04-14End: 2027-03-01Target: 240Updated: 2026-08-13
A Food Effect Study of JAB-21822 in Healthy Subjects
CompletedNCT05875493
Allist Pharmaceuticals, Inc.Food Effect in Healthy Participants
Start: 2023-05-12End: 2023-06-14Updated: 2025-04-04
A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects
CompletedNCT06162169
Allist Pharmaceuticals, Inc.Healthy Subjects
Start: 2023-11-25End: 2024-02-20Updated: 2025-04-04
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-21822 Monotherapy and Combination Therapy in Adult Patients with Advanced Solid Tumors Harboring KRAS G12C Mutation
CompletedCTIS2024-515258-25-00
Jacobio Pharmaceuticals Co. Ltd.advanced solid tumors with KRAS G12C mutation
End: 2024-12-27Target: 111Updated: 2024-11-18
JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC
Active, not recruitingNCT06838338
Jian LiColorectal Cancer
Start: 2025-03-20End: 2026-08-31Target: 30Updated: 2026-01-08

Phase 2

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
RecruitingNCT06008288
Allist Pharmaceuticals, Inc.KRAS P.G12C, Pancreatic Cancer, Solid Tumor
Start: 2023-10-27End: 2027-12-31Target: 88Updated: 2026-03-13

Phase 3

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
RecruitingNCT06416410
Allist Pharmaceuticals, Inc.Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
Start: 2024-08-07End: 2030-08-01Target: 392Updated: 2026-08-13

Related Papers

The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRAS<sup>G12C</sup> mutation.
2026-07-01
A phase Ib, open-label, clinical trial of JAB21822 combined with second-line chemotherapy for metastatic colorectal cancer with <i>KRAS</i> G12C mutation.
Journal of Clinical Oncology2026-05-27
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRAS&lt;sup&gt;G12C&lt;/sup&gt; mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials.
2025-12-01
Glecirasib plus sitneprotafib in patients with KRAS&lt;sup&gt;G12C&lt;/sup&gt;-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial.
2025-11-28
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials.
2025-10-026 citations
JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Clinical Cancer Research2025-05-073 citations
Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312
Cancer Research Communications2025-04-303 citations
Efficacy and safety of glecirasib (JAB-21822) monotherapy and in combination with cetuximab in patients with KRAS G12C-mutated advanced colorectal cancer.
Journal of Clinical Oncology2025-01-276 citations
Glecirasib in KRAS&lt;sup&gt;G12C&lt;/sup&gt;-mutated nonsmall-cell lung cancer: a phase 2b trial.
2025-01-0617 citations
Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with <i>KRAS p.G12C</i> mutated solid tumors.
Journal of Clinical Oncology2024-06-0117 citations
A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation.
Journal of Clinical Oncology2024-04-3018 citations
Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors.
Journal of Clinical Oncology2024-01-2029 citations
A phase I/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors.
Journal of Clinical Oncology2022-06-0131 citations